Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Thrombosis Journal

Fig. 3

From: Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

Fig. 3

Plasma concentration–time curves in children aged a 12–18 years given 10 mg-equivalent rivaroxaban, b 12–18 years given 20 mg-equivalent rivaroxaban, c 6–12 years given 10 mg-equivalent rivaroxaban, d 6–12 years given 20 mg-equivalent rivaroxaban, e 2–6 years given 10 mg-equivalent rivaroxaban, f 2–6 years given 20 mg-equivalent rivaroxaban, g 0.5–2 years given 10 mg-equivalent rivaroxaban and h 0.5–2 years given 20 mg-equivalent rivaroxaban. The solid black line shows the geometric mean of the population prediction, the dark grey shaded area denotes the 90% prediction interval of the PBPK model. The light grey shading denotes the enlarged expected concentration range representing 0.5-times the 5th percentile and 1.5-times the 95th percentile of the PBPK prediction. Data points represent clinically observed data from individual subjects (blue: tablet formulation, orange: undiluted suspension, green: diluted suspension). The inset panels show the same data as the respective main panel on a semi-logarithmic concentration scale eq., equivalent; PBPK, physiologically based pharmacokinetic.

Back to article page